Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2022

View Archived Issues

Novel TLR4 murine model to study dermal sensitization by nickel salts

AZD-9574: a selective PARP1 inhibitor suitable for cancer treatment

New hederagenin derivatives display multidrug resistance reversal in tumors

AIMer RNA base editing oligonucleotides edit ACTB transcript in the liver of nonhuman primates

Sichuan Haisco Pharmaceutical patents JAK3 inhibitors

Shanghai Haiju Biotechnology divulges new platinum complexes for cancer

New Mat2A inhibitors synthesized by ScinnoHub Pharmaceutical

Merck & Co. presents new KLKB1 inhibitors

Shanghai Litedd presents new RET inhibitors

LY-3372689, a novel OGA enzyme inhibitor for the treatment of Alzheimer's disease

Discovery of alpha-syn aggregation inhibitors for the treatment of PD

Researchers present [11C]JMJ-81 as a new PET tracer for brain PDE4D quantification

JS-009 cleared to advance into clinic in U.S. for advanced solid tumors

Blockade of PTGDR protects mice from severe SARS-CoV-2 infection

Molecular chaperone maintains proteostasis by clearing protein aggregates in cell

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...